Navigation Links
Study Suggests Invega Helps Patients With Schizophrenia Maintain,,,Symptom Control

52-Week Trial Maintained Improvement in Personal and Social Performance

COLORADO SPRINGS, Colo., March 30, 2007 /PRNewswire/ -- Longer-term treatment with INVEGA(TM) (paliperidone) Extended-Release Tablets, a new once daily oral medication for schizophrenia, helped many patients effectively control their symptoms and maintain their improvements in personal and social functioning.

These latest data are from a large, open label, international clinical trial sponsored by Janssen, L.P., the U.S. marketer of INVEGA, and were presented today at the International Congress on Schizophrenia Research (ICOSR). INVEGA was approved last December by the U.S. Food and Drug Administration for the treatment of schizophrenia.

"Schizophrenia imposes serious, lifelong psychological, physical, social, and economic burdens on patients, caregivers and heath care systems worldwide," said Herb Meltzer, MD, Bixler/May/Johnson Professor of Psychiatry & Pharmacology at the Vanderbilt University School of Medicine. "I am encouraged by the results of this pooled analysis because of the need for antipsychotic treatment options that provide effective symptom control, good tolerability, and which help to sustain the ability of patients to function over the long term."

In a pre-planned analysis, researchers evaluated data from 1,083 patients at 168 centers across North America, Europe, Asia, South Africa, and 12 other countries in the open-label extension (OLE) of three similarly designed six- week double-blind studies. In the 52-week OLE phase of the studies, the patients maintained effective symptom control and the improvement in personal and social performance achieved during the six-week double-blind phase.

These studies provided longer-term follow-up to the three previously completed six-week, placebo-controlled trials that demonstrated efficacy and
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:10/8/2008)...atments for Spinal Cord, Other Nerve,Injuries -, ...protein that enables,nerve cells to communicate wi...developing nervous system. Research into how that ...rve cells may provide a basis for eventual,treatme...ous system,including spinal cord injury., "This ...
(Date:10/8/2008)...continued and Headcount to be Reduced, Summary: Ge...; Zanolimumab Program to be Discontinued and the ... Employees, COPENHAGEN, October 8 /P...unced today that it is discontinuing development o...sult of a portfolio review and,assessment of the o...
(Date:10/8/2008)...TAXUS(R) Element(TM) Platinum Chromium ... /- Boston Scientific,Corpo...ompleted enrollment in,the PERSEUS trial, designed...R) Element(TM) paclitaxel-eluting coronary stent. ...,500 patients at 100 U.S. and,international center...
(Date:10/8/2008)... -- Vical Incorporated (Nasdaq: VICL ),today is p...al data,demonstrating that the company,s Vaxfectin... protein-based infectious disease vaccines and,pep...m.D., Ph.D., Vical,s,Senior Vice President of Prod...esday, October 8, at the World Vaccine Congress (L...
Breaking Medicine Technology:Protein Shown to Play a Key Role in Normal Development of Nervous System 2Protein Shown to Play a Key Role in Normal Development of Nervous System 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Saving Lives of Florida Residents Who Develop Skin Cancer Each Year 3A The Key is Early Detection and Treatment 252 1Saving Lives of Florida Residents Who Develop Skin Cancer Each Year 3A The Key is Early Detection and Treatment 252 2CABI helps phase out dangerous pesticide in EU 356 1CABI helps phase out dangerous pesticide in EU 356 2Microbiotic technology developed for microinjection of zebrafish embryos 1069 1Family Dinners Shape Healthier Eating Habits 1065 1
...--May 15, 2007 - Synthetic Blood,International, In...,a statistical analysis of its Phase IIa study wit...ury. In line with preliminary,study results announ...d that the primary endpoint of increasing patients... met. Data also show a,decrease in patient glucose...
... 17, 2007 - Salix,Pharmaceuticals, Ltd. (NASDAQ:SL...r-initiated trials related to the Company,s produc...2007, which will be,held May 19-24, 2007. Digestiv...prestigious meeting in the world for the GI,profes...ysicians,researchers and academics from around th...
Other Medicine Technology:Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 2Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 2Salix Pharmaceuticals Previews Digestive Disease Week 2007 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 4Salix Pharmaceuticals Previews Digestive Disease Week 2007 5
(Date:10/11/2008)...ot Pose Setback and Expects the 89-Year-Old ...ILLE, N.C., Oct. 11 /PRNewswire/ -- Evangelist Bil...treat, N.C. upon his release this,afternoon from M...ief stay.,He was admitted for observation after he...Friday., Mr. Graham,s physicians said that he suf...
(Date:10/10/2008)...orm of disease by 20 years after operation, study ...) -- Liver transplant patients have a higher incid...searchers in Finland. , In a new study publish..., researchers investigated the cancer risk pattern...elsinki University Central Hospital. The patients ...
(Date:10/10/2008)...ewswire/ -- Do you think that the blind,can,t use ...nd the October,17 open house at the Virginia Rehab..., and see how instructors there empower the blind ...ng lives through non-visual,techniques taught at t...nue, is holding an open house to,celebrate the gra...
(Date:10/10/2008)...RNewswire/ -- NuView Life Sciences Inc.,(NuView) h...ces Inc.,(Trace), including operations of the line... in Denton, Texas. The Trace facility produces,Cop...llium-201 used in,molecular imaging and nuclear me...d that "We are confident that by improving operati...
Breaking Medicine News(10 mins):Health News:Billy Graham Returns Home Following Hospital Observation 2Health News:Liver Transplant Patients at Higher Cancer Risk 2Health News:Virginia Rehabilitation Center for the Blind and Vision Impaired Celebrates Opening of New Student Dormitory 2
... the journal Environmental Health Perspectives had...astics on human beings. Bisphenol-A (BPA) is a ch...s food grade materials for making air tight contai...ding bottles for infants. The scientists from Yale...
...ers of UK, scientists have found that traveling by...od of the passengers. The study was done to see wh...ce today, do have any effect on the health of the ...ers have taken the measurement of peripheral oxyge...
...o be a risk factor for multiple sclerosis. New stu...eneration more in people suffering from multiple s...Harvard school of medicine, researchers had been a... rapid progression of the condition of multiple sc...
...hma, it may help if they take corticosteroid medic...ory medication regularly. People who took corticos...k had the same rate of severe attacks and asthma r...se who were treated with the standard treatment of...
Other Medicine News:
...dy (IgG) Test is a semiquantitative enzyme immunoa...cant IgG antibodies to M. pneumoniae between acute...should not be used for specimens found reactive wi... Test and is not intended for qualitative (one spe...
...unoassay (EIA) that detects IgG antibodies to Epst...arr early nuclear antigen (EBV-EBNA), cytomegalovi...n with Mono-M Test it is an aid in the serodiagnos...ve serodiagnosis of CMV or Toxoplasma mononucleosi...
The ImmunoDOT TORCH Test is an enzyme immunoassay (EIA) procedure intended for determining the presence of antibodies to Toxoplasma gondii, rubella virus, cytomegalovirus and herpes simplex virus in
...e enzyme immunoassays (EIA) for the presumptive de... IgM, respectively) in serum. Equivocal or positiv...with a standardized western blot procedure. These ...ical diagnosis of B. burgdorferi infection (Lyme d...
Medicine Products: